Micrometer‐scale tPA beads amplify plasmin generation for enhanced thrombolytic therapy

IF 6.1 2区 医学 Q1 ENGINEERING, BIOMEDICAL
Matthew J. Osmond, Fabrice Dabertrand, Nidia Quillinan, Enming J. Su, Daniel A. Lawrence, David W. M. Marr, Keith B. Neeves
{"title":"Micrometer‐scale tPA beads amplify plasmin generation for enhanced thrombolytic therapy","authors":"Matthew J. Osmond, Fabrice Dabertrand, Nidia Quillinan, Enming J. Su, Daniel A. Lawrence, David W. M. Marr, Keith B. Neeves","doi":"10.1002/btm2.70012","DOIUrl":null,"url":null,"abstract":"Rapid restoration of blood flow is critical in treating acute ischemic stroke. Current thrombolytic therapies using tissue plasminogen activator (tPA) are limited by low recanalization rates and risks of off‐target bleeding. Here, we demonstrate that a remarkably simple adjustment—using micrometer‐scale rather than sub‐micrometer particles to immobilize tPA—fundamentally improves thrombolysis. By merely increasing the particle diameter from 0.1 to 1.0 μm, we achieve a dramatic shift in lysis dynamics: 1.0 μm tPA‐beads generate higher plasmin flux, readily overcome antiplasmin inhibition, and trigger a self‐propagating cascade of fibrinolysis. This leads to near‐complete clot dissolution at tPA doses nearly 100‐fold lower than standard free tPA, both in vitro and in a murine model of acute ischemic stroke. Within minutes, low‐dose 1.0 μm tPA beads fully restore blood flow, outperforming conventional therapies. Our results show that simply scaling up particle size can resolve kinetic and transport barriers in thrombolysis, offering a promising advancement in stroke treatment with potential applications in other thrombotic disorders.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"54 1","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioengineering & Translational Medicine","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1002/btm2.70012","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Rapid restoration of blood flow is critical in treating acute ischemic stroke. Current thrombolytic therapies using tissue plasminogen activator (tPA) are limited by low recanalization rates and risks of off‐target bleeding. Here, we demonstrate that a remarkably simple adjustment—using micrometer‐scale rather than sub‐micrometer particles to immobilize tPA—fundamentally improves thrombolysis. By merely increasing the particle diameter from 0.1 to 1.0 μm, we achieve a dramatic shift in lysis dynamics: 1.0 μm tPA‐beads generate higher plasmin flux, readily overcome antiplasmin inhibition, and trigger a self‐propagating cascade of fibrinolysis. This leads to near‐complete clot dissolution at tPA doses nearly 100‐fold lower than standard free tPA, both in vitro and in a murine model of acute ischemic stroke. Within minutes, low‐dose 1.0 μm tPA beads fully restore blood flow, outperforming conventional therapies. Our results show that simply scaling up particle size can resolve kinetic and transport barriers in thrombolysis, offering a promising advancement in stroke treatment with potential applications in other thrombotic disorders.
微米级tPA珠可扩增纤溶蛋白的产生,增强溶栓治疗
快速恢复血流是治疗急性缺血性脑卒中的关键。目前使用组织型纤溶酶原激活剂(tPA)的溶栓治疗受到再通率低和脱靶出血风险的限制。在这里,我们证明了一个非常简单的调整-使用微米级而不是亚微米级的颗粒来固定tpa -从根本上改善了血栓溶解。仅通过将颗粒直径从0.1 μm增加到1.0 μm,我们就实现了溶解动力学的巨大变化:1.0 μm tPA珠产生更高的纤溶酶通量,容易克服抗纤溶酶抑制,并触发纤维蛋白溶解的自我传播级联。这导致在体外和急性缺血性中风小鼠模型中,tPA剂量比标准游离tPA低近100倍时,血栓几乎完全溶解。在几分钟内,低剂量1.0 μm tPA微珠完全恢复血流,优于常规治疗。我们的研究结果表明,简单地扩大颗粒大小可以解决血栓溶解中的动力学和运输障碍,为中风治疗提供了有希望的进展,并可能应用于其他血栓性疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Bioengineering & Translational Medicine
Bioengineering & Translational Medicine Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
8.40
自引率
4.10%
发文量
150
审稿时长
12 weeks
期刊介绍: Bioengineering & Translational Medicine, an official, peer-reviewed online open-access journal of the American Institute of Chemical Engineers (AIChE) and the Society for Biological Engineering (SBE), focuses on how chemical and biological engineering approaches drive innovative technologies and solutions that impact clinical practice and commercial healthcare products.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信